| Drug General Information |
| Drug ID |
D05ORO
|
| Former ID |
DIB002359
|
| Drug Name |
Anti-N3pG-Abeta antibody
|
| Drug Type |
Antibody
|
| Indication |
Alzheimer disease [ICD9: 331; ICD10:G30]
|
Phase 1 |
[1]
|
|---|
| Target and Pathway |
| Target(s) |
Amyloid beta A4 protein |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
Notch signaling pathway
|
|
Alzheimer's disease
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Degradation of the extracellular matrix
|
|
Regulated proteolysis of p75NTR
|
|
NRIF signals cell death from the nucleus
|
|
Activated NOTCH1 Transmits Signal to the Nucleus
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
EPH-ephrin mediated repulsion of cells
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Signaling by ERBB4
|
|
Signaling by NOTCH3
|
|
Signaling by NOTCH4
|
|
Signaling by NOTCH1
|
|
Signaling by NOTCH2
|
|
Notch Signaling Pathway
|
|
Alzheimers Disease
|
|
Signalling by NGF
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01837641) A Study of LY3002813 in Participants With Alzheimer's Disease. U.S. National Institutes of Health. |
|---|
| REF 2 | LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co. |
|---|
